Raymond Penn

Dr. Raymond Penn

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2017 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
YPY. S. Prakash
Y. S. Prakash
AHAndrew J. Halayko
Andrew J. Halayko
RGReinoud Gosens
Reinoud Gosens
RPReynold A. Panettieri
Reynold A. Panettieri
BCBlanca Camoretti-Mercado
Blanca Camoretti-Mercado
RPRaymond Penn
Raymond Penn
Background: Airway remodeling (AR) is a prominent feature of asthma and other obstructive lung diseases that is minimally affected by current treatments. The goals of this Official American Thoracic Society (ATS) Research Statement are to discuss the scientific, technological, economic, and regulatory issues that deter progress of AR research and development of therapeutics targeting AR and to propose approaches and solutions to these specific problems. This Statement is not intended to provide clinical practice recommendations on any disease in which AR is observed and/or plays a role. Methods: An international multidisciplinary group from within academia, industry, and the National Institutes of Health, with expertise in multimodal approaches to the study of airway structure and function, pulmonary research and clinical practice in obstructive lung disease, and drug discovery platforms was invited to participate in one internet-based and one face-to-face meeting to address the above-stated goals. Although the majority of the analysis related to AR was in asthma, AR in other diseases was also discussed and considered in the recommendations. A literature search of PubMed was performed to support conclusions. The search was not a systematic review of the evidence. Results: Multiple conceptual, logistical, economic, and regulatory deterrents were identified that limit the performance of AR research and impede accelerated, intensive development of AR-focused therapeutics. Complementary solutions that leverage expertise of academia and industry were proposed to address them. Conclusions: To date, numerous factors related to the intrinsic difficulty in performing AR research, and economic forces that are disincentives for the pursuit of AR treatments, have thwarted the ability to understand AR pathology and mechanisms and to address it clinically. This ATS Research Statement identifies potential solutions for each of these factors and emphasizes the importance of educating the global research community as to the extent of the problem as a critical first step in developing effective strategies for: (1) increasing the extent and impact of AR research and (2) developing, testing, and ultimately improving drugs targeting AR.

1 August 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SMSarah J. Morgan
Sarah J. Morgan
DDDeepak A. Deshpande
Deepak A. Deshpande
BTBrian C. Tiegs
Brian C. Tiegs
AMAnna M. Misior
Anna M. Misior
HYHuandong Yan
Huandong Yan
RPRaymond Penn
Raymond Penn
Inhaled β-agonists are effective at reversing bronchoconstriction in asthma, but the mechanism by which they exert this effect is unclear and controversial. PKA is the historically accepted effector, although this assumption is made on the basis of associative and not direct evidence. Recent studies have asserted that exchange protein activated by cAMP (Epac), not PKA, mediates the relaxation of airway smooth muscle (ASM) observed with β-agonist treatment. This study aims to clarify the role of PKA in the prorelaxant effects of β-agonists on ASM. Inhibition of PKA activity via expression of the PKI and RevAB peptides results in increased β-agonist-mediated cAMP release, abolishes the inhibitory effect of isoproterenol on histamine-induced intracellular calcium flux, and significantly attenuates histamine-stimulated MLC-20 phosphorylation. Analyses of ASM cell and tissue contraction demonstrate that PKA inhibition eliminates most, if not all, β-agonist-mediated relaxation of contracted smooth muscle. Conversely, Epac knockdown had no effect on the regulation of contraction or procontractile signaling by isoproterenol. These findings suggest that PKA, not Epac, is the predominant and physiologically relevant effector through which β-agonists exert their relaxant effects.

1 June 2014 in Current Opinion in Pharmacology
Verified
Journal Article
Closed access
TPTonio Pera
Tonio Pera
RPRaymond Penn
Raymond Penn

1 August 2016 in Pharmacology & Therapeutics
Verified
Journal Article
Closed access
TPTonio Pera
Tonio Pera
RPRaymond Penn
Raymond Penn

4 January 2018 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TPTonio Pera
Tonio Pera
DDDeepak A. Deshpande
Deepak A. Deshpande
MIMichael Ippolito
Michael Ippolito
BWBin Wang
Bin Wang
AGAdelina Gavrila
Adelina Gavrila
RPRaymond Penn
Raymond Penn
GPCRs have diverse signaling capabilities, based on their ability to assume various conformations. Moreover, it is now appreciated that certain ligands can promote distinct receptor conformations and thereby bias signaling toward a specific pathway to differentially affect cell function. The recently deorphanized G protein‐coupled receptor OGR1 [ovarian cancer G protein‐coupled receptor 1 ( GPR68 )] exhibits diverse signaling events when stimulated by reductions in extracellular pH. We recently demonstrated airway smooth muscle cells transduce multiple signaling events, reflecting a diverse capacity to couple to multiple G proteins. Moreover, we recently discovered that the benzodiazepine lorazepam, more commonly recognized as an agonist of the γ‐aminobutyric acid A(GABA A ) receptor, can function as an allosteric modulator of OGR1 and, similarly, can promote multiple signaling events. In this study, we demonstrated that different benzodiazepines exhibit a range of biases for OGR1, with sulazepam selectively activating the canonical Gs of the G protein signaling pathway, in heterologous expression systems, as well as in several primary cell types. These findings highlight the potential power of biased ligand pharmacology for manipulating receptor signaling qualitatively, to preferentially activate pathways that are therapeutically beneficial.—Pera, T., Deshpande, D. A., Ippolito, M., Wang, B., Gavrila, A., Michael, J. V., Nayak, A. P., Tompkins, E., Farrell, E., Kroeze, W. K., Roth, B. L., Panettieri, R. A. Jr., Benovic, J. L., An, S. S., Dulin, N. O., Penn, R. B. Biased signaling of the proton‐sensing receptor OGR1 by benzodiazepines. FASEB J. 32, 862–874 (2018). www.fasebj.org

5 November 2013
Verified
Book Chapter
Closed access
PDF file
RPRaymond Penn
Raymond Penn
RBRichard A. Bond
Richard A. Bond
JWJulia K. L. Walker
Julia K. L. Walker